By proceeding, you agree to our Terms of Use and Privacy Policy.
Dr. Hong MA is a seasoned medical oncologist with almost 20 years of cancer immunotherapy and orphan drug development experience, including over 15 years of pharmaceutical industry experience.
Talks About #immunotherapy #cellulartherapy #oncology
Preferred Locations #NorthAmerica
There aren’t many targets like BCMA - well validated, preferentially expressed by mature B lymphocytes and specific to multiple myeloma – meaning that novel drugs against BCMA continue to emerge.